C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes

Thrombosis and Haemostasis

Volumn 99, Issue 3, 2008, Pages 558-569

  Hanriot, Didier ^a,b   Bello, Gaëlle ^a,b   Ropars, Armelle ^a,b   Seguin Devaux, Carole ^d   Poitevin, Gaël ^a,b   Grosjean, Sandrine ^c   Latger Cannard, Véronique ^a,b,c   Devaux, Yvan ^a,b,d   Zannad, Faiez ^a,b   Regnault, Véronique ^a,b   Lacolley, Patrick ^a,b   Mertes, Paul Michel ^a,b   Hess, Ketsia ^a,b   Longrois, Dan ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Liver X receptors; Microarrays

Indexed keywords

ABC TRANSPORTER A1; ACTIVIN RECEPTOR; ALPHA 2 MACROGLOBULIN; C REACTIVE PROTEIN; CD64 ANTIGEN; CHEMOKINE; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; LIVER X RECEPTOR ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ADULT; ARTICLE; CELL LINE; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; WESTERN BLOTTING;

ADULT; ANTIGENS, CD14; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 42249102444     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0410     Document Type: Article

References (56)

1. Faxon DP, Creager MA, Smith SC, Jr., et al. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2004; 109: 2595-604.
2. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
3. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-1226.
4. Faxon DP, Fuster V, Libby P, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004; 109: 2617-2625.
5. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
6. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.
7. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
8. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
9. Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004; 31: 1095-1097.
10. Lowbeer C, Gutierrez A, Gustafsson SA, et al. Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. Nephrol Dial Transplant 2002; 17: 2178-2183.
11. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
12. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099.
13. Mold C, Du Clos TW. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fcγ receptors. J Immunol 2006; 176: 7598-7604.
14. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 2006; 71: 30-39.
15. Baugh LR, Hill AA, Brown EL, et al. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res 2001; 29: E29.
16. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
17. Chen CH, Seguin-Devaux C, Burke NA, et al. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med 2003; 197: 1689-1699.
18. Khreiss T, Jozsef L, Potempa LA, et al. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110: 2713-2720.
19. Khreiss T, Jozsef L, Potempa LA, et al. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 2005; 97: 690-697.
20. Hundt M, Zielinska-Skowronek M, Schmidt RE. Lack of specific receptors for C-reactive protein on white blood cells. Eur J Immunol 2001; 31: 3475-3483.
21. Stein MP, Edberg JC, Kimberly RP, et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 2000; 105: 369-376.
22. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25: 1225-1230.
23. Liu C, Wang S, Deb A, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res 2005; 97: 135-143.
24. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-993.
25. Mold C, Rodriguez W, Rodic-Polic B, et al. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002; 169: 7019-7025.
26. Williams TN, Zhang CX, Game BA, et al. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcγRII and extracellular signal-regulated kinase pathway:: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24: 61-66.
27. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917-1923.
28. Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108: 2041-2048.
29. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
30. Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, et al. C-reactive protein increases production of IL-1α, IL-1β, and TNF-α, and expression of mRNA by human alveolar macrophages. J Leukoc Biol 1993; 53: 439-445.
31. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-723.
32. Tilg H, Vannier E, Vachino G, et al. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J Exp Med 1993; 178: 1629-1636.
33. Hagiwara H, Mitsumata M, Yamane T, et al. Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells. Circulation 1998; 98: 2584-2590.
34. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823.
35. Nagase H. Activation mechanisms of matrix metalloproteinases. Biological Chemistry 1997; 378: 151-160.
36. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13: 455-481.
37. Szalai AJ, Nataf S, Hu XZ, et al. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002; 168: 5792-5797.
38. Taylor AW, Mortensen RF. Effect of α2-macroglobulin on cytokine-mediated human C-reactive protein production. Inflammation 1991; 15: 61-70.
39. Bunton DC, Petrie MC, Hillier C, et al. The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 2004; 103: 179-201.
40. Temmesfeld-Wollbruck B, Hocke AC, Suttorp N, et al. Adrenomedullin and endothelial barrier function. Thromb Haemost 2007; 98: 944-951.
41. Niemann-Jonsson A, Dimayuga P, Jovinge S, et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol 2000; 20: 2205-2211.
42. Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-716.
43. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-219.
44. Prufer K, Boudreaux J. Nuclear localization of liver X receptor alpha and beta is differentially regulated. J Cell Biochem 2007; 100: 69-85.
45. Watanabe Y, Jiang S, Takabe W, et al. Expression of the LXRalpha protein in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005; 25: 622-627.
46. Chen M, Li W, Wang N, et al. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the down-regulation of ATP-binding cassette transporter A1. Am J Physiol Cell Physiol 2007; 292: C1493-501.
47. Castrillo A, Joseph SB, Marathe C, et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 2003; 278: 10443-1049.
48. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109: 1870-1876.
49. Blaschke F, Takata Y, Caglayan E, et al. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res 2006; 99: e88-99.
50. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
51. Kovacs A, Tornvall P, Nilsson R, et al. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 2007; 104: 13768-13773.
52. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197.
53. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci USA 1997; 94: 2575-2580.
54. Zouki C, Beauchamp M, Baron C, et al. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997; 100: 522-529.
55. Sander K, Horn CS, Briesenick C, et al. High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE Study. Stroke 2007; 38: 2881-2886.
56. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.